[Perioperative strategies in patients with muscle invasive bladder cancer].
Radical cystectomy with bilateral pelvic lymph node dissection is the standard of care for patients with muscle-invasive bladder cancer, with 5-year survival rates not exceeding 60%. Consequently a multidisciplinary approach including perioperative chemotherapy and/or radiation therapy is required to improve these results. Data from clinical trials and meta-analyses with neoadjuvant chemotherapy have shown a significant benefit in overall survival, with a 5% absolute benefit at five years, provided cisplatin-based combination chemotherapy is used. Reported trials do not support the routine use of adjuvant chemotherapy. The current role of radiation therapy is limited to highly selected cases with a combination of external radiotherapy, partial cystectomy and interstitial brachytherapy.
CRLC Val-d'Aurelle, Service d'oncologie médicale, 208, rue des Apothicaires 34298 Montpellier, France.
D
D
Pouessel
J
J
Thariat
J-L
JL
Lagrange
N
N
Mottet
S
S
Culine
D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D018714:Radiotherapy, Adjuvant; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*